LINCOLN, Neb., Nov 12, 2010 (BUSINESS WIRE) -- Celerion, the premier provider of innovative early stage drug development solutions, announces implementation of the electronic laboratory notebook in our global bioanalytical network.
Celerion designed and implemented Labnotes, a commercially available electronic laboratory notebook system to standardize bioanalytical processes and improve documentation consistency for all studies.
Clients benefit from faster access to data and improved information quality due to centralized data repositories. Real time data integrity eliminates manual calculations and sources of potential error.
The electronic laboratory notebook has built-in calculations for critical aspects of the bioanalytical workflow, standardizing everything from reference standards, to instrument and pipette calibration. The system increases consistency and significantly reduces sources of manual error. The electronic laboratory notebook is validated to OECD GLP and FDA 21 CFR Part 11 computerized system regulatory requirements.
"The implementation of the electronic laboratory notebook continues to demonstrate Celerion's commitment to leveraging innovative technologies to provide our clients faster access to higher quality data," said Susan Thornton, President and CEO of Celerion. "This system standardizes bioanalytical processes, improves documentation consistency for all studies, and supports the generation of data in a validated electronic environment across our global facilities." Celerion collaborated with Laboratory Data Solutions Ltd on their Labnotes electronic laboratory notebook product. "We are delighted to have worked with Celerion on implementing the Labnotes solution" said Jeremy Cook, Director of Laboratory Data Solutions. "The team at Celerion has invested significant time in ensuring the system is completely integrated into the bioanalytical workflow, clearly demonstrating they are leaders in this field." About Celerion Celerion is the premier provider of innovative early stage clinical research solutions. Formed through the acquisition of the early stage development operations of MDS Pharma Services, Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (Phases 0, I and IIa), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. For more information, please visit www.celerion.com.
About Labnotes Labnotes is a commercially available solution that can be configured to comply with the differing data recording requirements of most laboratory environments.
Labnotes has been implemented in a number of bioanalytical laboratories and has demonstrated significant improvements in quality and productivity. For more information please visit www.labnotes.com.
SOURCE: Celerion CONTACT: Celerion Media Contact: Farzana Azam, +1 (647) 261 3628 Senior Director, Global Marketing firstname.lastname@example.org Copyright Business Wire 2010 -0- KEYWORD: United States
Nebraska INDUSTRY KEYWORD: Technology
Science SUBJECT CODE: Product/Service